Ustekinumab (Stelara and biosimilars)
An interleukin-blocking biologic: one drip to start, then injections at home every few weeks
In short
- Ustekinumab is an interleukin inhibitor that blocks IL-12 and IL-23.
- Stelara was the first brand; several biosimilars, such as Pyzchiva, Uzpruvo and Wezenla, are now used.
- The first dose is a drip in hospital; after that it is an injection under the skin with long gaps between doses.
- Most people who respond feel better within six to eight weeks, but it can take up to 16 weeks.
- In trials, side effects were about as common as with a dummy treatment, but infections are still possible and live vaccines should be avoided.
Get help if
Call 999 or go to A&E
- You have signs of a heart attack or stroke, such as chest pain, a drooping face, weakness on one side or slurred speech. Crohn's & Colitis UK says to get urgent medical care.
- You have difficulty breathing or swallowing, or swelling of your face, lips, mouth or throat. The NHS says these can be signs of anaphylaxis, a life-threatening allergic reaction: call 999 straight away.
Urgent GP appointment or NHS 111
- You think you are having a milder allergic reaction, such as a raised, itchy rash (hives) or feeling dizzy. Crohn's & Colitis UK says to contact NHS 111 straight away.
Contact your IBD team
- You think you have an infection, or develop a sun-sensitive rash with joint pains. Contact your GP, IBD team or NHS 111 straight away.
In an emergency call 999. For urgent advice call 111 or use 111 online. 12
On this page
What is ustekinumab and how does it work?
Ustekinumab is a biologic medicine. Crohn's & Colitis UK calls it an interleukin inhibitor. Interleukins are proteins that help control the immune system. Ustekinumab blocks two of them, interleukin 12 and interleukin 23 (IL-12 and IL-23), which play a key part in long-lasting inflammation in the gut. Blocking them eases some of the inflammation behind Crohn's symptoms.13
Stelara was the original brand. Crohn's & Colitis UK lists several biosimilars, including Imuldosa, Otulfi, Pyzchiva, Steqeyma, Usymro, Uzpruvo, Wezenla and Yesintek. It says these work in the same way and the brand you are given will not affect your treatment, although the ingredients and shelf life may differ slightly. Your medicine is prescribed by brand name.1
Who is it for?
Ustekinumab is used for adults with moderate to severe Crohn's, and for children who weigh at least 40kg. It can only be prescribed by a hospital specialist. Your IBD team might suggest it if standard treatments, or another biologic, have not worked, have stopped working, have caused bad side effects or are not suitable.1
NICE recommends ustekinumab for adults with moderate to severe Crohn's when standard treatment or an anti-TNF medicine has not worked well enough, has stopped working, was not tolerated or is unsuitable. NICE says the choice between ustekinumab and other biologics should be made with you after talking through the pros and cons, and if more than one is suitable, the least expensive should be used. It asks for treatment to be reassessed after 12 months.4
Ustekinumab is one of the advanced medicines the 2025 BSG guideline suggests for moderate to severe Crohn's, alongside the anti-TNF medicines, risankizumab and upadacitinib. On this medicine, NICE and the BSG broadly agree.45
How is it given?
Ustekinumab cannot be taken as a tablet, because the gut would break it down. The first dose is a drip into a vein in hospital, which takes about an hour, followed by a short period of monitoring. After that, it is given as an injection under the skin, usually into the thigh or tummy. A nurse often gives the first injection at home, and later you can be trained to inject yourself, or a family member can be trained.1
One of the attractions for many people is that the injections are spaced weeks apart rather than every week or two. Your team decides how often you need them, and may shorten the gap or give another drip if symptoms return. The injections are delivered to your home and kept in the fridge.16
How quickly does it work, and how well?
Crohn's & Colitis UK says some people feel better as early as three weeks, most who respond do so within six to eight weeks, and some take up to 16 weeks. Your team may suggest stopping if it has not worked by 16 weeks after the first drip, or 16 weeks after moving to more frequent injections.1
In two large trials, about 24 in 100 people were in remission six weeks after starting ustekinumab, compared with 13 in 100 on placebo. In a follow-on trial of people who had responded and were in remission, about 51 in 100 who stayed on ustekinumab were still in remission 44 weeks later, compared with 36 in 100 who were switched to placebo. Crohn's & Colitis UK says real-world results have been similar, and long-term follow-up found around half of responders still in remission after five years. Small studies suggest it may help some people with fistulas around the bottom, but the evidence is limited.1
A head-to-head trial called SEQUENCE compared ustekinumab with risankizumab in people for whom anti-TNF treatment had not worked well enough or had caused unacceptable side effects. Risankizumab was at least as good for symptom remission at 24 weeks and better at healing the gut lining at 48 weeks.7
What checks will I need?
Before you start, your team will check for infections, including TB (usually with a blood test and chest X-ray), hepatitis and HIV, and ask about chickenpox, shingles and cold sores. They will make sure your vaccines are up to date. Tell them if you are allergic to latex, because some needle covers contain it.1
Once you are on treatment, you will have regular checks on your symptoms, side effects and how you are managing the injections. You may have blood tests and poo tests (faecal calprotectin). Crohn's & Colitis UK says your team may also look at your risk factors for heart attack and stroke. You should have a check-up at least once a year.1
What side effects can it cause?
Crohn's & Colitis UK says that in trials, side effects were about as common with ustekinumab as with a dummy treatment. Up to 1 in 10 people may get colds, sore throats or sinus infections, dizziness, headache, diarrhoea, feeling or being sick, itching, back or joint pain, tiredness, or pain and redness where they inject.1
Up to 1 in 100 people may get more serious infections, such as chest or skin infections or shingles. Serious allergic reactions are rare. Very rarely, people develop a lupus-like condition with a rash on sun-exposed skin and joint pains. Clinical trials found a similar rate of cancer to the general population, but you may be offered skin checks, and sun protection is sensible. Some people make antibodies against ustekinumab over time, which Crohn's & Colitis UK puts at around 5 in 100 over two to five years.1
Crohn's & Colitis UK says there is no evidence that ustekinumab interacts with other medicines, and it can be taken alongside steroids or immunosuppressants. If you are on steroids when you start, you may be able to reduce them gradually, but only with your team's guidance.1
Vaccines, pregnancy and breastfeeding
Crohn's & Colitis UK says live vaccines should be avoided during treatment and for 15 weeks or more after the final dose. The yearly flu jab, COVID-19 and pneumococcal vaccines are not live and are safe, and people on ustekinumab generally respond well to vaccines.1
The manufacturers advise effective contraception during treatment and for at least 15 weeks afterwards. Studies so far have not found problems in pregnancy, but the numbers are small, so the manufacturers suggest not taking it while pregnant. Crohn's & Colitis UK says experts consider it probably low risk, and that you and your team should weigh up the benefits against any risk. If you took it while pregnant, tell your baby's health team, because live vaccines such as rotavirus and BCG may need to wait. Very small amounts pass into breast milk and many babies have been safely breastfed.1
Sources
This article is written in our own words from these sources. Each number in the text points to one of them.
- Crohn's & Colitis UK Ustekinumab Read on the Crohn's & Colitis UK website: Ustekinumab
- NHS Anaphylaxis Read on the NHS website: Anaphylaxis
- Crohn's & Colitis UK Biologic medicines and other targeted treatments Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Biologic medicines and other targeted treatments
- NICE Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456) Guideline, Jul 2017 Read on the NICE website: Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
- Frontline Gastroenterology (via PMC) Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease Guide, Nov 2025 Read the paper: Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease
- Royal Free London NHS Foundation Trust Starting biologic medication Leaflet, Aug 2025 Read the Royal Free London NHS Foundation Trust leaflet: Starting biologic medication
- New England Journal of Medicine Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE) Study, Jul 2024 Read the paper: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)